DRES-17. BCL3 IS A 19q PASSENGER THAT PREDICTS RESPONSE TO ALKYLATING CHEMOTHERAPY IN GBM

INTRODUCTION: Despite the universal use of temozolomide (TMZ) in GBM, many patients experience minimal benefit. Moreover, TMZ can be deleterious due to its mutagenic nature. These findings underline the importance of predicting which patients will benefit from TMZ. DATA: Bcl-3 was identified as bein...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wu, Longtao, Bernal, Giovanna, Cahill, Kirk, Pytel, Peter, Yamini, Bakhtiar
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691882/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.275
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados